Virtu Financial’s Virax Biolabs VRAX Stock Holding History

Virtu Financial’s Portfolio VRAX Stock Details VRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-855	Closed	-$13K	–	2288
2025 Q3	$13K	Buy	+855	New	+$16.3K	﹤0.01%	1323
2024 Q3	–	Sell	-1,122	Closed	-$33K	–	1930
2024 Q2	$33K	Buy	+1,122	New	+$27.8K	﹤0.01%	963
2024 Q1	–	Sell	-426	Closed	-$16K	–	2149
2023 Q4	$16K	Buy	+426	New	+$24.9K	﹤0.01%	1354
2023 Q1	–	Sell	-194	Closed	-$35K	–	2142
2022 Q4	$35K	Buy	+194	New	+$68.9K	﹤0.01%	1154

Other funds holding VRAX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

Virtu Financial's VRAX Position: Q4 2025 in Review

Virtu Financial sold out of Virax Biolabs (VRAX) in Q4 2025, closing a stake of 855 shares — an estimated $13K sold.

Virtu Financial first reported a position in VRAX in Q4 2022 and held it in 4 quarters. The position peaked at $35K in Q4 2022. 5 funds tracked by Wall St. Rank hold VRAX as of Q4 2025.

Virtu Financial reported no remaining Virax Biolabs position as of Q4 2025 after selling out during the quarter.
Virtu Financial sold 855 Virax Biolabs shares in Q4 2025, an estimated $13K.
Virtu Financial first reported a position in Virax Biolabs in Q4 2022 and held it in 4 quarters.
Virtu Financial's Virax Biolabs position peaked at $35K in Q4 2022.
5 funds tracked by Wall St. Rank held Virax Biolabs as of Q4 2025.

Based on Virtu Financial's 13F filing for Q4 2025, filed 23 Feb 2026.